Relation Therapeutics is a London-based TechBio firm using active-graph machine learning, single-cell multi-omics and clinical data to discover medicines, starting with bone diseases such as osteoporosis.
Relation Therapeutics is a TechBio company based in London that applies active-graph machine learning to drug discovery. Its approach combines computational models with single-cell analysis - including single-cell multi-omics - and clinical data to build a detailed picture of disease mechanisms. The company's stated aim is to develop transformational medicines for devastating diseases, beginning with bone-related conditions such as osteoporosis.
Central to its work is the Lab-in-the-Loop platform, which integrates single-cell multi-omics from patient tissue, functional assays and computational methods. The platform is designed to trace disease from cause to cure, using experimental results to inform and refine machine-learning models in an iterative process. Technical work spans computational biology, functional assay development and the application of active-graph methods to biological data.
The company operates an end-to-end biotech model that unites high-resolution biology, machine learning and clinical insight within a single organisation, positioning technology at the core of its drug-discovery efforts. It has raised over $60M in seed funding and has strategic partnerships with GSK, Novartis and Deerfield Management.
